↓ Skip to main content

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

Overview of attention for article published in British Journal of Dermatology, July 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
4 X users
patent
1 patent

Citations

dimensions_citation
89 Dimensions

Readers on

mendeley
87 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis
Published in
British Journal of Dermatology, July 2018
DOI 10.1111/bjd.16736
Pubmed ID
Authors

C. Ryan, A. Menter, L. Guenther, A. Blauvelt, R. Bissonnette, K. Meeuwis, J. Sullivan, J.C. Cather, G. Yosipovitch, A.B. Gottlieb, J.F. Merola, K. Callis Duffin, S. Fretzin, O.O. Osuntokun, R. Burge, A.N. Naegeli, F.E. Yang, C.‐Y. Lin, K. Todd, A. Potts Bleakman, the IXORA‐Q Study Group

Abstract

Genital psoriasis (GenPs) is a common, debilitating, and difficult to treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist. To determine the efficacy of ixekizumab versus placebo in patients with moderate-to-severe GenPs with BSA≥1%. Subjects with moderate-to-severe GenPs (defined as a baseline static Physician's Global Assessment of Genitalia [sPGA-G] score of ≥3) with BSA≥1% were randomized 1:1 to receive placebo (N=74) or the recommended dosing of ixekizumab (N=75). Major outcomes included the percentage of patients achieving 0 or 1 scores on the sPGA-G (primary endpoint), overall sPGA, GenPs Sexual Frequency Questionnaire (GenPs-SFQ) item 2, and a ≥3-point improvement from baseline on the GenPs itch numeric rating scale. At week 12, ixekizumab was superior to placebo on the sPGA-G 0/1 (73.3% versus 8.1%, p<0.001), overall sPGA 0/1 (73.3% versus 2.7%, p<0.001), GenPs-SFQ item 2 0/1 (78.4% versus 21.4%, p<0.001), and genital itch (59.7% versus 8.3%, p<0.001). No candidiasis was reported, no deaths occurred, and one (1.4%) serious adverse event was reported in a patient receiving placebo. Ixekizumab was superior to placebo for the treatment of moderate-to-severe GenPs with BSA≥1%. The safety profile of ixekizumab was consistent with previous studies in moderate-to-severe plaque psoriasis. This article is protected by copyright. All rights reserved.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 87 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 11%
Student > Master 8 9%
Student > Doctoral Student 8 9%
Unspecified 7 8%
Student > Ph. D. Student 6 7%
Other 16 18%
Unknown 32 37%
Readers by discipline Count As %
Medicine and Dentistry 27 31%
Unspecified 7 8%
Nursing and Health Professions 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Psychology 3 3%
Other 7 8%
Unknown 35 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2019.
All research outputs
#6,446,325
of 25,382,440 outputs
Outputs from British Journal of Dermatology
#2,682
of 9,663 outputs
Outputs of similar age
#102,340
of 340,797 outputs
Outputs of similar age from British Journal of Dermatology
#42
of 179 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 9,663 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,797 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.